Oncology

Pre-clinical data showed that EZ-T cells have increased anti-tumor activity compared with traditional iPSC-derived T-cells.

The chief of the lymphoma division and oncologist at Levine Cancer Institute discussed work that needs to be done to support the use of CAR T therapy.

Review top news and interview highlights from the week ending August 5, 2022.

Topline results are expected to be announced by the fourth quarter of 2022.

Incidences of graft versus host disease will be a focal point of the study.

Avenge Bio previously presented positive preclinical data at the ASGCT 2022 meeting.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

UCART2022 is an allogeneic therapy that targets both CD20 and CD22.

Omidubicel demonstrated neutrophil engraftment a median of 10 days faster than standard UCBT.

The company voluntarily paused the trial in February 2022 to investigate 2 reported deaths in the trial.

Milan Zdravkovic, MD, PhD, chief medical officer of SNIPR Biome, discussed the company’s ongoing research on targeting E Coli in the blood with CRISPR-based medication.

Review top news and interview highlights from the week ending July 29, 2022.

The associate professor at Fred Hutch Cancer Center discussed next steps with the clinical trial being conducted Fred Hutch Cancer Center.

CYTO-102 is being developed by City of Hope and CytoImmune.

The chief of the lymphoma division and oncologist at Levine Cancer Institute discussed new CAR T-cell therapies being investigated for hematologic malignancies.

CYNK-101 has previously been granted fast track and orphan drug designation.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

All 3 patients remained progression-free at more than 1 year post-treatment.

Nilanjan Ghosh, MD, PhD, discussed the impact of liso-cel's approval.

In preclinical studies, OBX-115 demonstrated improved TIL persistence, potency, and tumor control compared with unengineered TILs.

The chief medical officer of Triumvira Immunologics discussed promising early results from the company’s phase 1/2 clinical trial.

The chief of the oncology branch of the Center for Biologics Evaluation and Research at the FDA discussed how academia and industry can work best with regulatory agencies.

The chief medical officer of Triumvira Immunologics discussed the company’s TAC platform and its versatile target-recognizing domain.

Review top news and interview highlights from the week ending July 22, 2022.

WU-CART-007 has been granted fast track, rare pediatric disease, and orphan drug designations.